FY2027 EPS Estimates for Precigen Lowered by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Research analysts at HC Wainwright decreased their FY2027 earnings estimates for Precigen in a research note issued on Thursday, May 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.17 per share for the year, down from their previous forecast of $0.18. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Precigen Stock Performance

Shares of NASDAQ PGEN opened at $1.45 on Friday. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17. The firm’s 50 day moving average price is $1.50 and its 200 day moving average price is $1.30. The firm has a market cap of $427.99 million, a P/E ratio of -2.64 and a beta of 1.82.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $0.50 million.

Hedge Funds Weigh In On Precigen

A number of large investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. raised its stake in Precigen by 3.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock worth $16,801,000 after purchasing an additional 410,595 shares during the period. Iridian Asset Management LLC CT raised its stake in Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after purchasing an additional 1,465,962 shares during the period. Geode Capital Management LLC raised its stake in Precigen by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after purchasing an additional 53,343 shares during the period. Parkman Healthcare Partners LLC purchased a new position in Precigen during the first quarter worth approximately $4,755,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Precigen by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock worth $1,432,000 after purchasing an additional 56,012 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.